Participate in MDMA Studies
We are currently recruiting for the Phase 3 study of MDMA-assisted therapy for PTSD. Here is a list of all MAPS-sponsored trials on clinicaltrials.gov.
Read our Publications
MAPS PBC publishes research papers detailing the results of our clinical trials.
MAPS PBC in the Media
The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.
May 09, 2021
A Psychedelic Drug Passes Big Test for PTSD Treatment
May 03, 2021
New PTSD Treatments Emerge as Cases Rise Among Some Groups
Sept. 21, 2020
PTSD and psychoactive drugs: MDMA treatment shows potential, but others lack evidence
Sept. 21, 2020
The case for funding psychedelics to treat mental health
Oct 9, 2020
Announcements
Publication of MAPP1 Results in Nature Medicine: A Message from Amy Emerson, MAPS PBC CEO
We’ve finally reached the point where we can shout our good news from the roof tops and publicly celebrate the work of this amazing team! The publication of our MAPP1 findings is official as of this morning, May 10th, in Nature Medicine! Nature Medicine is one of the...
MAPS PBC Announces Frontiers in Psychiatry Published First Study to Evaluate Neural Impact of MDMA-Assisted Therapy in Patients with PTSD
Results demonstrate a biological correlation between reduction in PTSD severity and treatment with MDMA-assisted therapy in veterans and first responders Study sheds light on neurological mechanisms that drive MDMA-assisted therapy in PTSD SAN JOSE, Calif.,...
MAPS PBC Announces Positive Results from Confirmatory Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for Treatment of PTSD
Results met study pre-specified primary and key secondary endpoints and will support new drug application submission expected in third quarter of 2023 No serious adverse events observed in the MDMA group If approved, MAPS PBC’s MDMA-assisted therapy could be the...
MAPS PBC Completes Second Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for Treatment of PTSD
Top-line data expected in the first quarter of 2023 Data to be part of new drug application submission expected in third quarter of 2023 SAN JOSE, Calif., November 17, 2022—MAPS Public Benefit Corporation (“MAPS PBC”), a private company dedicated to the development...
MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.